7,542.52

-37.55

-0.50%

52,013.67

+243.36

+0.47%

25,153.73

-283.27

-1.11%

2,810.04

-1.80

-0.06%

4.8940

-0.0350

-0.71%

21.70

+2.28

+11.72%

3,953.40

+54.50

+1.40%

76,652.02

-1,133.34

-1.46%

Crude Oil Dec 26

95.96

-8.16

-7.84%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqGM - Nasdaq Real Time Price USD

Neuphoria Therapeutics Inc. (NEUP)

3.0000 -0.0500 (-1.64%)

As of 3:25:10 PM EST. Market Open.

Loading Chart for NEUP

Chart Range Bar

Interval:

In partnership with ChartIQ

Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development

Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development

Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell

Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders

Lynx1 Sends Open Letter to Fellow Neuphoria Shareholders

Scancell confirms advanced talks over reverse merger with Neuphoria

Scancell confirms advanced talks over reverse merger with Neuphoria

Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial

Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial

Scancell sees high demand in retail share offer, seals £15.7m from UK investors

Scancell sees high demand in retail share offer, seals £15.7m from UK investors

SMALL-CAP MOVERS: Nasdaq-bound Scancell catches the eye as AIM's headcount falls to 612

SMALL-CAP MOVERS: Nasdaq-bound Scancell catches the eye as AIM's headcount falls to 612

Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing

Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing

MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership

MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership

Leading Advisory Firms Recommend Voting FOR Lynx1's Independent Nominees

Leading Advisory Firms Recommend Voting FOR Lynx1's Independent Nominees

Mobilize your Website

View Site in Mobile | Classic

Share by: